Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Hans van Vliet, Paul W. H. I. Parren, Rieneke van de Ven, Jana Vree, Roeland Lameris, Tanja D. de Gruijl, Renate de Boer, Anita G.M. Stam, George L. Scheffer, Arnon P. Kater, Steven T. Pals, Mark-David Levin, Rob C. Roovers, Iris de Weerdt
Publikováno v:
Cancer immunology research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.
Cancer Immunology Research, 9(1), 50-61. AMER ASSOC CANCER RESEARCH
de Weerdt, I, Lameris, R, Scheffer, G L, Vree, J, de Boer, R, Stam, A G, van de Ven, R, Levin, M-D, Pals, S T, Roovers, R C, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies ', Cancer Immunology Research, vol. 9, no. 1, pp. 50-61 . https://doi.org/10.1158/2326-6066.CIR-20-0138
Cancer Immunology Research, 9(1), 50-61. American Association for Cancer Research Inc.
Novel T cell-based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been hampered by low efficacy and high toxicity.
Autor:
Tanja D. de Gruijl, Rik J. Scheper, M. Petrousjka van den Tol, Mari F.C.M. van den Hout, Paul A. M. van Leeuwen, Berbel J.R. Sluijter, Bas D. Koster, Alfons J.M. van den Eertwegh, Barbara G. Molenkamp, Rieneke van de Ven
Publikováno v:
Van Den Hout, M F C M, Koster, B D, Sluijter, B J R, Molenkamp, B G, Van De Ven, R, Van Den Eertwegh, A J M, Scheper, R J, Van Leeuwen, P A M, Van Den Tol, M P & De Gruijl, T D 2017, ' Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence ', Cancer Immunology Research, vol. 5, no. 11, pp. 969-977 . https://doi.org/10.1158/2326-6066.CIR-17-0110
Cancer Immunology Research, 5(11), 969-977. American Association for Cancer Research Inc.
Cancer immunology research, 5(11), 969-977. American Association for Cancer Research Inc.
Cancer Immunology Research, 5(11), 969-977. American Association for Cancer Research Inc.
Cancer immunology research, 5(11), 969-977. American Association for Cancer Research Inc.
Melanoma exerts immune-suppressive effects to facilitate tumor progression and metastatic spread. We studied these effects on dendritic cell (DC) and T-cell subsets in 36 melanoma sentinel lymph node (SLN) from 28 stage I–III melanoma patients and
Autor:
André Lieber, Joao Manuel Santos, Hongjie Wang, Riikka Havunen, Suvi Sorsa, Anna Kanerva, Victor Cervera-Carrascon, Sadia Zafar, Akseli Hemminki, Mikko Siurala, Otto Hemminki, Tanja D. de Gruijl
Publikováno v:
Cancer Immunology Research. 8:B07-B07
Dendritic cell (DC) therapy is considered a promising immunotherapeutic approach for treatment of advanced cancer. However, the immunosuppressive tumor microenvironment leads to DC dysfunction. Therefore, in clinical trials DC therapy has generally f
Autor:
Dafne Carolina Alves Quixabeira, Anna Kanerva, Mikko Siurala, Tanja D. de Gruijl, Joao Manuel Santos, Akseli Hemminki, Heini Lassus, Victor Cervera-Carrascon, Camilla Heiniö
Publikováno v:
Cancer Immunology Research. 8:A15-A15
The natural occurrence of immune cells in the tumor microenvironment of ovarian cancer (OC) facilitates the ex vivo generation and expansion of tumor-infiltrating lymphocytes (TIL) for infusion in the context of adoptive T-cell transfer. Yet, the lac
Autor:
Marc Bonneville, Emmanuel Scotet, Tom O'Toole, Famke L. Schneiders, Rik J. Scheper, Tanja D. de Gruijl, Jurjen M. Ruben, Hans van Vliet, Henk M.W. Verheul, Jan Prodöhl
Publikováno v:
Cancer immunology research. 2(8)
CD1d-restricted invariant natural killer T cells (iNKT) constitute an important immunoregulatory T-cell subset that can be activated by the synthetic glycolipid α-galactosylceramide (α-GalCer) and play a dominant role in antitumor immunity. Clinica
Autor:
Bas D. Koster, Dafni Chondronasiou, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Ronald J.C.L.M. Vuylsteke, Tanja D. de Gruijl, Kim M. van Pul, Sinéad M. Lougheed, Anita G.M. Stam, Karin Ute Jooss
Publikováno v:
Cancer Immunology Research. 4:B138-B138
While systemic immune checkpoint blockade is unsurpassed in the induction of clinically effective T cell immunity in advanced-stage melanoma patients, the risk of autoimmune-related side effects precludes its application in earlier stages. In a Phase
Autor:
Paul A. M. van Leeuwen, Alfons J.M. van den Eertwegh, M. Petrousjka van den Tol, Bas D. Koster, Barbara G. Molenkamp, Rik J. Scheper, Mari F.C.M. van den Hout, Tanja D. de Gruijl, Berbel J.R. Sluijter
Publikováno v:
Cancer Immunology Research. 4:A050-A050
Although 5-year overall survival rates in patients with Stage I-II melanoma range from 95% to as low as 45%, currently there is no adjuvant treatment available that has been shown to reduce the chances of recurrence after surgical excision of localiz